Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

doi:10.1016/j.lungcan.2019.11.022

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2020

Tan Aaron C, Lai Gillianne G Y, Tan Gek San, Poon Shou Yu, Doble Brett, Lim Tse Hui, Aung Zaw Win, Takano Angela, Tan Wan Ling, Ang Mei-Kim, Tan Bien Soo, Devanand Anantham, Too Chow Wei, Gogna Apoorva, Ong Boon-Hean, Koh Tina P T, Kanesvaran Ravindran, Ng Quan Sing, Jain Amit, Rajasekaran Tanujaa, Lim Alvin S T, Lim Wan Teck, Toh Chee Keong, Tan Eng-Huat, Lim Tony Kiat Hon, Tan Daniel S W

Abstract excerpt

OBJECTIVES: There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsies is an increasingly encountered problem. We sought to compare the performance of targeted next-generation sequencing (NGS) panels with traditional assays and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Asia

Share to Carcinoma, Non-Small-Cell Lung

Share to Cost-Benefit Analysis

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Molecular Targeted Therapy

Source

Open in PubMed

Identifiers

PMID: 31835042
DOI: 10.1016/j.lungcan.2019.11.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.PMID 31835042Read ↗

Association of Next Generation Sequencing and Routine Testing With Clinical Outcomes of Advanced Non-small Cell Lung Cancer Patients in a Real-world SettingSemantic proximity Read ↗

Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancerSemantic proximity Read ↗

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.Semantic proximity Read ↗

Next-Generation Sequencing in Lung Cancers-A Single-Center Experience in Taiwan.Semantic proximity Read ↗

Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.Semantic proximity Read ↗

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.Semantic proximity Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.Semantic proximity Read ↗

Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.Semantic proximity Read ↗

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.